Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors.
De Luca G, Gibson MC, Hof AW, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel MH, Secco GG, Emre A, Dudek D, Rakowski T, Gyongyosi M, Huber K, Bellandi F; EGYPT cooperation. De Luca G, et al. Among authors: gibson mc. J Cardiovasc Med (Hagerstown). 2013 Nov;14(11):815-20. doi: 10.2459/JCM.0b013e32835fcb38. J Cardiovasc Med (Hagerstown). 2013. PMID: 23519096
Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.
De Luca G, Gibson M, Cutlip D, Huber K, Dudek D, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Secco GG, Mesquita Gabriel H, Emre A, Arntz HR, Rakowski T, Gyongyosi M, Hof AW; EGYPT Cooperation. De Luca G, et al. Arch Cardiovasc Dis. 2013 Mar;106(3):155-61. doi: 10.1016/j.acvd.2012.12.007. Epub 2013 Apr 2. Arch Cardiovasc Dis. 2013. PMID: 23582677 Free article.
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.
Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, Dangas G, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta S, Moliterno DJ, Ohman EM, Oldroyd KG, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Escaned J, et al. Eur Heart J. 2021 Dec 1;42(45):4624-4634. doi: 10.1093/eurheartj/ehab702. Eur Heart J. 2021. PMID: 34662382 Clinical Trial.
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
Dehghani P, Cao D, Baber U, Nicolas J, Sartori S, Pivato CA, Zhang Z, Dangas G, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta S, Moliterno DJ, Ohman EM, Escaned J, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Dehghani P, et al. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):707-716. doi: 10.1093/ehjcvp/pvac016. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 35325085 Clinical Trial.
A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale.
Sardella G, Sangiorgi GM, Mancone M, Colantonio R, Donahue M, Politi L, Bucciarelli-Ducci C, Carbone I, Francone M, Ligabue G, Fiocchi F, Di Roma A, Benedetti G, Lucisano L, Stio RE, Agati L, Modena MG, Genuini I, Fedele F, Gibson M. Sardella G, et al. J Cardiovasc Med (Hagerstown). 2010 Jul;11(7):529-35. doi: 10.2459/JCM.0b013e3283341c1c. J Cardiovasc Med (Hagerstown). 2010. PMID: 19918189 Clinical Trial.
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index.
Kunadian V, Baber U, Pivato CA, Cao D, Dangas G, Sartori S, Zhang Z, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Dehghani P, Mehta S, Moliterno DJ, Ohman EM, Escaned J, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Džavík V, Gurbel P, Hamm CW, Henry T, Kastrati A, Marx SO, Oldroyd K, Steg PG, Pocock S, Mehran R. Kunadian V, et al. JACC Cardiovasc Interv. 2022 Oct 10;15(19):1948-1960. doi: 10.1016/j.jcin.2022.07.039. JACC Cardiovasc Interv. 2022. PMID: 36202563 Free article. Clinical Trial.
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis.
Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, McFadden EP, Vranckx P, Angiolillo DJ, Leonardi S, Cao D, Dangas GD, Mehta SR, Serruys PW, Gibson CM, Steg GP, Sharma SK, Hamm C, Shlofmitz R, Liebetrau C, Briguori C, Janssens L, Huber K, Ferrario M, Kunadian V, Cohen DJ, Zurakowski A, Oldroyd KG, Yaling H, Dudek D, Sartori S, Kirkham B, Escaned J, Heg D, Windecker S, Pocock S, Jüni P; SIDNEY Collaboration. Valgimigli M, et al. JACC Cardiovasc Interv. 2021 Feb 22;14(4):444-456. doi: 10.1016/j.jcin.2020.11.046. JACC Cardiovasc Interv. 2021. PMID: 33602441 Free article.
Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study.
Kaya MG, Akpek M, Lam YY, Yarlioglues M, Celik T, Gunebakmaz O, Duran M, Ulucan S, Keser A, Oguzhan A, Gibson MC. Kaya MG, et al. Among authors: gibson mc. Int J Cardiol. 2013 Sep 30;168(2):1154-9. doi: 10.1016/j.ijcard.2012.11.074. Epub 2012 Dec 5. Int J Cardiol. 2013. PMID: 23219132
SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention.
Tcheng JE, Gibson M, Krucoff MW, Patel MR, Ajit M, Hiremath J, Ponde C, Ramsaran E, Clark G, Lader AS, Beeuwkes R 3rd; SUPPORT-1 Investigators. Tcheng JE, et al. J Cardiovasc Pharmacol. 2020 Aug;76(2):189-196. doi: 10.1097/FJC.0000000000000830. J Cardiovasc Pharmacol. 2020. PMID: 32769849 Clinical Trial.
98 results